Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era

References

• Connors JM. Risk assessment in the management of newly diagnosed classical Hodgkin lymphoma. Blood. 2015;125(11):1693.
   PubMed Web of Science ®Google Scholar
• Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93(5):704.
   PubMed Web of Science ®Google Scholar
• Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004;104(12):3483.
   PubMed Web of Science ®Google Scholar
• Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial ofabvdversus stanfordvwith or without radiation therapy in locally extensive and advanced-stage hodgkin lymphoma: an intergroup study coordinated by the eastern cooperative oncology group (E2496). J Clin Oncol. 2013;31(6):684–691.
   PubMed Web of Science ®Google Scholar
• Xing KH, Connors JM, Lai A, et al. Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: A matched pair outcome analysis. Blood. 2014;123(23):3567.
   PubMed Web of Science ®Google Scholar
• Connors JM, Ansell SM, Fanale M, et al. Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced stage classical Hodgkin lymphoma. Blood. 2017;130(11):1375.
   PubMed Web of Science ®Google Scholar
• Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14(13):1348–1356.
   PubMed Web of Science ®Google Scholar
• Kumar A, Casulo C, Yahalom J, et al. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016;128(11):1458.
   PubMed Web of Science ®Google Scholar
• Bonadonna G, De Lena M, Monfardini S, et al. Clinical trials with bleomycin in lymphomas and in solid tumors. Eur J Cancer. 1972;8(2):205–215.
   PubMed Web of Science ®Google Scholar
• Umezawa H, Ishizuka M, Maeda K, et al. Studies on bleomycin. Cancer. 1967;20(5):891–895.
   PubMed Web of Science ®Google Scholar
• Jules-Elysee K, White DA. Bleomycin-induced pulmonary toxicity. Clin Chest Med. 1990;11(1):1–20.
   PubMed Web of Science ®Google Scholar
• Sleijfer S. Bleomycin-induced pneumonitis. Chest. 2001;120(2):617–624.
   PubMed Web of Science ®Google Scholar
• Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol. 2005;23(30):7614–7620.
   PubMed Web of Science ®Google Scholar
• Hoskin PJ, Lowry L, Horwich A, et al. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin’s Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol. 2009;27(32):5390–5396.
   PubMed Web of Science ®Google Scholar
• Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012;119(3):692.
   PubMed Web of Science ®Google Scholar
• Hirsch A, Vander Els N, Straus DJ, et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin’s disease. J Clin Oncol. 1996;14(4):1297–1305.
   PubMed Web of Science ®Google Scholar
• Sun HL, Atenafu EG, Tsang R, et al. Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma. Leuk Lymphoma. 2017;58(11):2607–2614.
   PubMed Web of Science ®Google Scholar
• Jóna Á, Miltényi Z, Ujj Z, et al. Late pulmonary complications of treating Hodgkin lymphoma: bleomycin-induced toxicity. Expert Opin Drug Saf. 2014;13(10):1291–1297.
   PubMed Web of Science ®Google Scholar
• Avivi I, Hardak E, Shaham B, et al. Low incidence of long-term respiratory impairment in Hodgkin lymphoma survivors. Ann Hematol. 2012;91(2):215–221.
   PubMed Web of Science ®Google Scholar
• Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med. 2016;374(25):2419–2429.
   PubMed Web of Science ®Google Scholar
• Böll B, Goergen H, Behringer K, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016;127(18):2189–2192.
   PubMed Web of Science ®Google Scholar
• Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med. 2018;378(4):331–344.
   PubMed Web of Science ®Google Scholar
• Ansell SM. Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc. 2015;90(11):1574–1583.
   PubMed Web of Science ®Google Scholar
• Bellamy EA, Husband JE, Blaquiere RM, et al. Bleomycin-related lung damage: CT evidence. Radiology. 1985;156(1):155–158.
   PubMed Web of Science ®Google Scholar
• Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21):1478–1484.
   PubMed Web of Science ®Google Scholar
• Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol. 2003;21(4):607–614.
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V, Armitage JO, et al. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339(21):1506.
   PubMed Web of Science ®Google Scholar
• Khalil N, Whitman C, Zuo L, et al. Regulation of alveolar macrophage transforming growth factor-beta secretion by corticosteroids in bleomycin-induced pulmonary inflammation in the rat. J Clin Invest. 1993;92(4):1812–1818.
   PubMed Web of Science ®Google Scholar
• Blum RH, Carter SK, Agre K. A clinical review of bleomycin–a new antineoplastic agent. Cancer. 1973;31(4):903–914.
   PubMed Web of Science ®Google Scholar
• Chandler DB. Possible mechanisms of bleomycin-induced fibrosis. Clin Chest Med. 1990;11(1):21–30.
   PubMed Web of Science ®Google Scholar
• Chen J, Stubbe J. Bleomycins: new methods will allow reinvestigation of old issues. Curr Opin Chem Biol. 2004;8(2):175–181.
   PubMed Web of Science ®Google Scholar
• Manoury B, Nenan S, Leclerc O, et al. The absence of reactive oxygen species production protects mice against bleomycin-induced pulmonary fibrosis. Respir Res. 2005;6(1):11.
   PubMed Web of Science ®Google Scholar
• Fantone JC, Phan SH. Oxygen metabolite detoxifying enzyme levels in bleomycin-induced fibrotic lungs. Free Radic Biol Med. 1988;4(6):399–402.
   PubMed Web of Science ®Google Scholar
• Phan SH, Kunkel SL. Lung cytokine production in bleomycin-induced pulmonary fibrosis. Exp Lung Res. 1992;18(1):29–43.
   PubMed Web of Science ®Google Scholar
• Piguet PF, Vesin C, Grau GE, et al. Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine. 1993;5(1):57–61.
   PubMed Web of Science ®Google Scholar
• Sikic BI. Biochemical and cellular determinants of bleomycin cytotoxicity. Cancer Surv. 1986;5(1):81–91.
   PubMedGoogle Scholar
• Lazo JS, Merrill WW, Pham ET, et al. Bleomycin hydrolase activity in pulmonary cells. J Pharmacol Exp Ther. 1984;231(3):583–588.
   PubMed Web of Science ®Google Scholar
• Nuver J, Lutke Holzik MF, van ZM, et al. Genetic variation in the bleomycin hydrolase gene and bleomycin-induced pulmonary toxicity in germ cell cancer patients. Pharmacogenet Genomics. 2005;15(6):399–405.
   PubMed Web of Science ®Google Scholar
• De Lena M, Guzzon A, Monfardini S, et al. Clinical, radiologic, and histopathologic studies on pulmonary toxicity induced by treatment with bleomycin (NSC-125066). Cancer Chemother Rep. 1972;56(3):343–356.
   PubMedGoogle Scholar
• Canellos GP, Duggan D, Johnson J, et al. How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? J Clin Oncol. 2004;22(8):1532–1533.
   PubMed Web of Science ®Google Scholar
• Haverkamp H, Böll B, Eichenauer DA, et al. Impact of bleomycin and vincristine dose reductions in patients with advanced Hodgkin lymphoma treated with BEACOPP: an analysis of the German Hodgkin Study Group HD12 and HD15 trials. J Clin Oncol. 2015;33(22):2430–2436.
   PubMed Web of Science ®Google Scholar
• Behringer K, Goergen H, Hitz F, et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015;385(9976):1418–1427.
   PubMed Web of Science ®Google Scholar
• Ramchandren R, Advani RH, Ansell SM, et al. Brentuximab vedotin plus chemotherapy in North American subjects with newly diagnosed stage III or IV Hodgkin lymphoma. Clin Cancer Res. 2019;25(6):1718.
   PubMed Web of Science ®Google Scholar